Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pirtobrutinib and Epcoritamab vs R-(Mini)-CHOP in DLBCL-type Richter Transformation
NCT07917780Phase 2Recruiting
- Sponsor
- German CLL Study Group
- Start
- Jun 2026
- Primary completion
- May 2030
- Countries
- 5
01
Overview
Phase 2, randomised, open-label trial of pirtobrutinib and epcoritamab in Richter's syndrome (RS), chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) (2 arms), sponsored by German CLL Study Group. Primary endpoint: Progression-Free Survival at 40 months. Started Jun 2026; status: recruiting.
02
Drugs
pirtobrutinibepcoritamab
03
Conditions
Richter's syndrome (RS)chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT07917780.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07917780.